A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.
about
Opioids and Viral Infections: A Double-Edged SwordEvaluation of Alum-Naltrexone Adjuvant Activity, on Efficacy of Anti-Leishmania Immunization with Autoclaved Leishmania major (MRHO/IR/75/ER) Antigens in BALB/C Mice.An HIV-1 Mini Vaccine Induced Long-lived Cellular and Humoral Immune Responses.Heat shock proteins enriched-promastigotes of Leishmania major inducing Th2 immune response in BALB/c mice.Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responsesPotentiation of human papilloma vaccine candidate using naloxone/alum mixture as an adjuvant: increasing immunogenicity of HPV-16E7d vaccine.A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine.Analysis of affinities between specific biological ligands using atomic force microscopy.Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis.Leishmaniasis in humans: drug or vaccine therapy?Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts.A novel adjuvant, the mixture of alum and naltrexone, augments vaccine-induced immunity against Plasmodium berghei.Administration of naloxone in combination with recombinant Plasmodium vivax AMA-1 in BALB/c mice induces mixed Th1/Th2 immune responses.Subcutaneous administration CpG-ODNs acts as a potent adjuvant for an HIV-1-tat-based vaccine candidate to elicit cellular immunity in BALB/c mice.
P2860
Q26742182-D7BBD19F-9A09-4B42-9401-8AC5C4CDECAAQ35047309-9567EF33-D969-4D95-B95D-BA9B310904C3Q36625724-E16C5403-6F63-4D66-A7D4-DA468BF1953DQ36694417-3C371DA4-705D-40F7-9189-2FAA134B3AF6Q36972226-62D275FD-8917-4287-8EE0-8E05918CEF79Q37366419-C001AAAB-50E0-4697-ADBB-6AC658CFDFCFQ44348323-DB29DFC4-F3D4-4C5C-A4EE-DB0643102970Q45021541-597C7C2B-F878-47D0-9E41-A7B2BA64286BQ45370073-4E1E4ED5-DD21-47F1-8E0D-024D666D9639Q47556262-9446EA4D-8323-4701-80F8-144F0E3D8243Q47562812-51A9CA1A-886B-4B1A-8537-2980D1C42ED7Q47875209-D3C6F0B1-ED1F-4278-AA51-6BB7E42C32EAQ47923410-B68E5E78-06A8-40EA-ACCE-A3609C667933Q50127638-6DF19BF8-14CC-43BC-86B6-5B42C98EAF2D
P2860
A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
A novel adjuvant, the general ...... ne response for a DNA vaccine.
@en
A novel adjuvant, the general ...... ne response for a DNA vaccine.
@nl
type
label
A novel adjuvant, the general ...... ne response for a DNA vaccine.
@en
A novel adjuvant, the general ...... ne response for a DNA vaccine.
@nl
prefLabel
A novel adjuvant, the general ...... ne response for a DNA vaccine.
@en
A novel adjuvant, the general ...... ne response for a DNA vaccine.
@nl
P2093
P2860
P50
P356
P1476
A novel adjuvant, the general ...... ne response for a DNA vaccine.
@en
P2093
Abbas Jamali
Farzaneh Sabahi
Hoorieh Soleimanjahi
Mohammad Jazayeri Farsani
Zuhair Muhammad Hassan
P2860
P304
P356
10.1093/INTIMM/DXN139
P577
2009-01-27T00:00:00Z